Novo Nordisk shares rose by more than 5% after scrutiny of Hims & Hers Health’s compounded semaglutide pill following an FDA warning. Hims plans to offer the drug at $49, while Novo’s brand costs $149.
Novo Nordisk shares rebound after FDA warning on illegal weight-loss drugs: Copycat maker Hims and Hers responds
